Tokyo High Court Reaches Settlement With 21 Hepatitis C Victims
This article was originally published in PharmAsia News
Following similar high court settlements with hepatitis C victims in Osaka and Fukuoka, Tokyo high court judge, Katsuya Kobayashi, announced a settlement with 21 plaintiffs on Feb. 29. The government will take responsibility for the infections caused by tainted blood products and pay ¥476 million to the victims. The victims will receive ¥40 million, ¥20 million and ¥12 million in compensation, respectively, according to the seriousness of symptoms. The Tokyo settlement adds to a total of 87 settled cases. Attorneys representing the hepatitis C victims also said that negotiations with pharmaceutical companies for a settlement are ongoing. (Click for more-Japanese language
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.